Risk of second primary malignancies after adjuvant chemotherapy for colon cancer.

ABSTRACT:

Background

Advances in adjuvant chemotherapy have improved survival in patients with stage II-III colon cancer (CC). However, concerns have emerged regarding the risk of second and subsequent primary malignancies (SPMs) based on preclinical data and registry-based studies. This study evaluated the incidence of SPMs among CC survivors in relation to adjuvant chemotherapy type.

Methods

This retrospective, population-based cohort study included 18,383 patients with stage II-III CC who were treated between 2010 and 2022. Patients were categorized based on three adjuvant treatments: (1) no chemotherapy, (2) fluorouracil or capecitabine alone, and (3) fluorouracil or capecitabine with oxaliplatin. Standardized incidence ratios (SIRs) for SPMs were calculated using national cancer

SUBMITTER: Buchler T 

PROVIDER: S-EPMC12506602 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature